Antibody Information
General Information of This Antibody
| Antibody ID | ANI0ZCTOG |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | A humanized IgG1 monoclonal antibody |
|||||
| Synonyms |
A humanized IgG1 monoclonal antibody
Click to Show/Hide
|
|||||
| Antigen Name | Tumor-associated calcium signal transducer 2 (TACSTD2) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
ESG-401 [Phase 3]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
36.40%
|
|||
| Patients Enrolled |
Patients (pts) aged 18 years with locally advanced/metastatic solid tumors refractory to/relapsed.
|
||||
| Administration Dosage |
Treated with 1 dose of ESG401 during escalation at doses of 2-20 mg/kg once Q3W (Regimen A), or 12-16 mg/kg D1,8,15 in a 4-week cycle (Regimen B).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04892342 | Clinical Status | Phase 1/2 | ||
| Clinical Description |
An open-label, multiple dose, dose escalation and cohort expansion phase 1/2 study to investigate the safety, tolerability, pharmacokinetics and antitumor activities of ESG401 in Subjects with locally advanced/metastatic solid tumors.
|
||||
References